Dr. Blaine McKee has over 25 years of experience building biotechnology companies and possesses extensive strategic, transactional, and market access expertise. Having worked in both large companies and start-ups, Dr. McKee’s experience includes executive roles at Genzyme Corporation, 480 BioMedical, Shire, and ImmunoGen.
Previously, as Executive Vice President and Chief Business Officer at ImmunoGen, Dr. McKee was responsible for leading the company’s broader corporate development function, including all transactional, alliance management, commercial assessment and planning, and valuation matters. At Shire, he served as Head of Corporate Development, leading the corporate strategy, M&A, business development/licensing, due diligence, commercial assessment, integration, and alliance management functions. Prior to joining Shire, Dr. McKee was Executive Vice President and Chief Business Officer at 480 Biomedical, a venture capital-backed medical device company.
During a 15-year tenure at Genzyme, Dr. McKee held a variety of senior strategy, business development, and market access roles, including serving as Senior Vice President of Strategic Development for the Oncology, Transplant, and Multiple Sclerosis divisions, and leading global business development activities for all three business. He started his career in the biopharmaceutical industry as a Research Scientist at Gilead Sciences, Inc.
Dr. McKee currently serves on the Board of VBI Vaccines Inc., where he is Chairman of the Audit Committee. He previously served on the boards of BioStage, Inc., ArmaGen, Inc., and The New York Pharma Forum. Dr. McKee received a B.S. in Chemistry from Colorado State University, a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology (MIT), and an MBA in Finance from the MIT Sloan School of Management.